Evidence map›Paper›PMID 39203963›Full record

ArticleVaccines2024

Nopprarat Tongmuang, Meera Krishnan, Viv Connor, Colin Crump, Liselotte E Jensen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Nopprarat TongmuangDepartment of Microbiology, Immunology and Inflammation, Temple University Lewis Katz School of Medicine, Philadelphia, PA 19104, USA.
Meera KrishnanDepartment of Microbiology, Immunology and Inflammation, Temple University Lewis Katz School of Medicine, Philadelphia, PA 19104, USA.
Viv ConnorDepartment of Pathology, University of Cambridge, Cambridge CB2 1QP, UK.
Colin CrumpDepartment of Pathology, University of Cambridge, Cambridge CB2 1QP, UK.ORCID 0000-0001-9918-9998
Liselotte E JensenDepartment of Microbiology, Immunology and Inflammation, Temple University Lewis Katz School of Medicine, Philadelphia, PA 19104, USA.ORCID 0000-0002-0267-8312

Funding

Interleukin-36 cytokines in antiviral immune responsesR01AI125111 · NIAID · TEMPLE UNIV OF THE COMMONWEALTH · PI JENSEN, LISELOTTE E · 2016 to 2020
$2.0M
Dynamic interplay between IL-36 and IL-1 in inflammation and infectionsR01AI178128 · NIAID · TEMPLE UNIV OF THE COMMONWEALTH · PI LISELOTTE E JENSEN · 2023 to 2026
$1.6M
IL-36 activity during skin infectionsR21AR082631 · NIAMS · TEMPLE UNIV OF THE COMMONWEALTH · PI JENSEN, LISELOTTE E · 2023 to 2023
$384k
NIAID NIH HHS R01 AI125111NIAID NIH HHS R01 AI178128NIAMS NIH HHS R21 AR082631The Medical Research Council MR/T016493/1The National Institute of Allergy and Infectious Diseases R01AI125111The National Institute of Allergy and Infectious Diseases R01AI178128The National Institute of Arthritis and Musculoskeletal and Skin Diseases R21AR082631
6 · The paper itself

Abstract

Herpes simplex virus-1 (HSV-1) is common and can cause significant disease in humans. Unfortunately, efforts to develop effective vaccines against HSV-1 have so far failed. A detailed understanding of how the virus infects its host and how the host mounts potent immune responses against the virus may inform new vaccine approaches. Here, using a zosteriform mouse model, we examined how the HSV-1 gene

Indexed as

herpes simplex virusHSVIL-1IL-1R1IL-1RAPIL-1RL2IL-36immune memoryUL56

Identifiers

PMID39203963
PMCPMC11359923

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.